Korsana Biosciences Inc(KRSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -11.76 | Insider Own | 1.27% | Shs Outstand | 45.5M | Perf Week | -7.73% |
| Market Cap | 1.43B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 45.0M | Perf Month | -10.23% |
| Enterprise Value | 1.43B | PEG | - | EPS next Q | -0.85 | Inst Own | 16.15% | Short Float | 0.03% | Perf Quarter | 21.44% |
| Income | -0.01B | P/S | 752.85 | EPS this Y | - | Inst Trans | 18.99% | Short Ratio | 0.27 | Perf Half Y | 49.57% |
| Sales | 0.00B | P/B | 3.75 | EPS next 5Y | - | ROA | -82.29% | Short Interest | 0.01M | Perf YTD | 253.32% |
| Book/sh | 8.37 | P/C | 1029.07 | EPS past 3/5Y | 62.05% 53.53% | ROE | -98.22% | 52W High | -47.09% ($59.36) | Perf Year | 100.32% |
| Cash/sh | 0.03 | P/FCF | - | Sales past 3/5Y | 91.14% -2.01% | ROIC | -131.85% | 52W Low | 337.09% ($7.19) | Perf 3Y | 38.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -126.24% | Gross Margin | - | Volatility(W/M) | 9.04% 10.37% | Perf 5Y | -91.57% |
| Dividend TTM | - | EV/Sales | 752.12 | Sales Y/Y TTM | -12.6% | Oper. Margin | -359.16% | ATR (14) | 3.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.82 | EPS Q/Q | -291.32% | Profit Margin | -353% | RSI (14) | 48.78 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.82 | Sales Q/Q | -100% | SMA20 | -3.8% ($32.65) | Beta | 1.85 | Target Price | $53 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/11 | SMA50 | 3.38% ($30.38) | Rel Volume | 8.04 | Prev Close | $32.38 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 49.12% ($21.06) | Avg Volume(3M) | 0.04M | Price | $31.41 |
| IPO | 2019/3/18 | Option/Short | No/Yes | Trades | 2067 | Volume | 346,103 | Change | -3% |
🧠 알츠하이머병을 시작으로 신경퇴행성 질환 치료제를 개발하는 임상 단계 바이오테크 기업입니다. 큰 분자 치료제를 혈뇌장벽 너머 중추신경계로 전달하는 자체 셔틀 플랫폼을 보유하고 있으며, 이를 적용한 항아밀로이드 베타 항체가 선도 후보물질입니다. 미국에 본사를 두고 있습니다.
Over the past 1 year, roughly in the middle
47% below its 1-year high.
Traded more than usual. That is 804% of its average volume.
KRSA has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $75,285. Peers typically go for $1,078.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.6%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 16.1%.
Tap to view numbers
It ranks #126 of 595 in the industry
Based on market cap of $1B.
ANAB#123 AnaptysBio Inc $1B PER 7.6 
ABSI#124 Absci Corp $1B PER - 
AAPG#125 Ascentage Pharma Group International ADR $1B PER - KRSA#126 Korsana Biosciences Inc $1B PER - 
OCUL#127 Ocular Therapeutix Inc $1B PER - 
FAQ
What kind of company is KRSA?
KRSA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KRSA?
The market cap of KRSA is approximately $1.4B, ranking 2,302 within its sector.
What is the 52-week high and low for KRSA?
KRSA has recorded a 52-week high of $59.36 and a low of $7.19.
